RNA, U6atac small nuclear 2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC2P profile across patient tissues and cancer cell-line models. RNU6ATAC2P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC2P is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RNU6ATAC2P RNA expression shows 5,207 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight DLBC, BRCA, and LSCC as cancer lineages where RNU6ATAC2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC2P survival associations across molecular data types. RNU6ATAC2P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC2P RNA expression–survival associations across cancer types. High RNU6ATAC2P expression shows unfavorable associations in DLBC, KIRP, BLCA, LUAD, THCA and HNSC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RNU6ATAC2P RNA expression.
This table summarizes RNU6ATAC2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC2P shows higher tumor expression in BRCA and LUSC. The BRCA box plot shows higher RNU6ATAC2P RNA expression in tumor versus normal tissue (log2 FC = +0.066, t-test p = .031).
This table shows molecular features associated with RNU6ATAC2P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC2P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
